Alejandra Palacios, president of the Federal Commission of Economic Competition (COFECE) of Mexico, declared that a lack of competition and abuse of market power by certain pharmaceutical companies in collusion with public authorities has meant that “Mexican households pay an average of 98 percent more than they would pay without surcharges ” when buying medicines.
Featured News
White House Finalizes Voluntary AI Cybersecurity Testing Framework
Aug 3, 2026 by
CPI
Apple Faces Russian Antitrust Investigation Tied to Domestic App Policy
Aug 3, 2026 by
CPI
Seoul Investigates Alleged Housing Price Collusion Through KakaoTalk Group
Aug 3, 2026 by
CPI
Axinn Hires Former DOJ, FTC Lawyers to Expand Antitrust Practice
Aug 3, 2026 by
CPI
Broadcom Loses Bid to Halt EU Antitrust Document Request
Aug 3, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes